Despite the clinical success of monoclonal and bispecific antibodies, there are still limitations in the therapeutic effect of malignant tumours, such as low response rate, treatment resistance, and so on, inspiring the exploration of trispecific antibodies (TsAbs). TsAbs further improve the safety and efficacy and has great clinical potential through three targets combination and formats optimization. This article reviews the development history and the target combination features of TsAbs. Although there are still great challenges in the clinical application of TsAbs, it is undeniable that TsAbs may be a breakthrough in the development of antibody drugs. © 2023 John Wiley & Sons Ltd.
Citation
Yin Yao, Yiyin Hu, Fei Wang. Trispecific antibodies for cancer immunotherapy. Immunology. 2023 Aug;169(4):389-399
Mesh Tags
Substances
PMID: 36855956
View Full Text
